Article Text

Download PDFPDF
Extended report
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study
  1. Seoyoung C Kim1,2,3,
  2. Sebastian Schneeweiss1,3,
  3. Robert J Glynn1,
  4. Michael Doherty1,
  5. Allison B Goldfine4,
  6. Daniel H Solomon1,2
  1. 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA
  2. 2Division of Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA
  3. 3Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
  4. 4Joslin Diabetes Center, Boston, Massachusetts, USA
  1. Correspondence to Dr Seoyoung C Kim, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030 Boston, MA 02120, USA; skim62{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.